| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PR3 |
| Uniprot No | P24158 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 26-249aa |
| 氨基酸序列 | AEIVGGHEAQPHSRPYMASLQMRGNPGSHFCGGTLIHPSFVLTAAHCLRD IPQRLVNVVLGAHNVRTQEPTQQHFSVAQVFLNNYDAENKLNDVLLIQLS SPANLSASVATVQLPQQDQPVPHGTQCLAMGWGRVGAHDPPAQVLQELNV TVVTFFCRPHNICTFVPRRKAGICFGDSGGPLICDGIIQGIDSFVIWGCA TRLFPDFFTRVALYVDWIRSTLRRVDHHHHHH |
| 预测分子量 | 26 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PR3重组蛋白的3篇参考文献示例(注：内容为模拟虚构，仅供参考)：
1. **标题**: "Expression and Purification of Recombinant Human Proteinase 3 for Autoantibody Detection in ANCA-Associated Vasculitis"
**作者**: Müller R, et al.
**摘要**: 该研究描述了在大肠杆菌中高效表达重组人PR3蛋白的方法，采用His标签纯化技术，验证其与患者血清中抗PR3抗体的结合能力，证实其在ANCA相关性血管炎诊断中的应用价值。
2. **标题**: "Structural Characterization of Recombinant PR3: Insights into Antigenic Epitopes and Enzymatic Activity"
**作者**: Zhang L, et al.
**摘要**: 通过X射线晶体学解析重组PR3的三维结构，分析其抗原表位分布及酶活性位点，揭示PR3与自身抗体相互作用的关键区域，为靶向治疗提供结构基础。
3. **标题**: "Functional Analysis of Recombinant PR3 in Neutrophil Extracellular Trap (NET) Formation"
**作者**: Johnson K, et al.
**摘要**: 研究证明重组PR3蛋白可促进中性粒细胞释放NETs，并验证其在炎症反应中的调控作用，提示PR3可能通过NETs途径加剧血管炎病理进程。
如需真实文献，建议在PubMed或Web of Science中以“recombinant proteinase 3”或“PR3 expression”为关键词检索。
PR3 (proteinase 3), a neutrophil serine protease, plays critical roles in inflammation and immune regulation. Primarily stored in azurophilic granules of neutrophils, it is released during neutrophil activation or apoptosis, contributing to pathogen clearance and tissue remodeling. PR3 gained clinical prominence due to its association with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), where autoantibodies against PR3 trigger vascular inflammation. Recombinant PR3 (rPR3) proteins are engineered versions produced via molecular cloning and expression systems (e.g., E. coli, mammalian cells), enabling standardized studies of its biological functions and disease mechanisms.
The development of rPR3 addresses challenges in isolating native PR3 from human sources, which is labor-intensive and yields low quantities. Recombinant technology allows precise control over protein purity and activity, facilitating structural studies, epitope mapping for ANCA interactions, and drug discovery. rPR3 retains enzymatic activity, enabling research on its substrate specificity and regulatory pathways. It also serves as a critical reagent in diagnostic assays for AAV, improving test reproducibility compared to native protein extracts.
Recent applications extend to therapeutic investigations, including targeted inhibitors for inflammatory diseases and biomarker validation. However, challenges persist in replicating post-translational modifications present in native PR3. prompting ongoing optimization of expression systems. rPR3 remains a vital tool for unraveling the complex roles of proteases in immunity and advancing precision medicine in autoimmune vasculitis.
×
